

Bohdan Nosyk

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8384380/publications.pdf>

Version: 2024-02-01

144
papers

3,959
citations

126901

33
h-index

161844

54
g-index

147
all docs

147
docs citations

147
times ranked

4010
citing authors

#	ARTICLE	IF	CITATIONS
1	Expansion of HAART Coverage Is Associated with Sustained Decreases in HIV/AIDS Morbidity, Mortality and HIV Transmission: The "HIV Treatment as Prevention" Experience in a Canadian Setting. PLoS ONE, 2014, 9, e87872.	2.5	272
2	Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence. JAMA Psychiatry, 2021, 78, 979.	11.0	244
3	The cascade of HIV care in British Columbia, Canada, 1996-2011: a population-based retrospective cohort study. Lancet Infectious Diseases, The, 2014, 14, 40-49.	9.1	178
4	A Call For Evidence-Based Medical Treatment Of Opioid Dependence In The United States And Canada. Health Affairs, 2013, 32, 1462-1469.	5.2	114
5	Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study. BMJ, The, 2020, 368, m772.	6.0	107
6	Mortality among individuals accessing pharmacological treatment for opioid dependence in California, 2006-2010. Addiction, 2015, 110, 996-1005.	3.3	93
7	Trends in methadone maintenance treatment participation, retention, and compliance to dosing guidelines in British Columbia, Canada: 1996-2006. Journal of Substance Abuse Treatment, 2010, 39, 22-31.	2.8	92
8	Polydrug use and its association with drug treatment outcomes among primary heroin, methamphetamine, and cocaine users. International Journal of Drug Policy, 2017, 49, 32-40.	3.3	87
9	Proportional Hazards Frailty Models for Recurrent Methadone Maintenance Treatment. American Journal of Epidemiology, 2009, 170, 783-792.	3.4	85
10	Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment. Cmaj, 2012, 184, E317-E328.	2.0	82
11	Client Demands for Unsafe Sex. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 522-531.	2.1	70
12	Safety and Clinical Effectiveness of Midazolam versus Propofol for Procedural Sedation in the Emergency Department: A Systematic Review. Academic Emergency Medicine, 2008, 15, 1-8.	1.8	62
13	High Levels of Heterogeneity in the HIV Cascade of Care across Different Population Subgroups in British Columbia, Canada. PLoS ONE, 2014, 9, e115277.	2.5	62
14	Defining dosing pattern characteristics of successful tapers following methadone maintenance treatment: results from a population-based retrospective cohort study. Addiction, 2012, 107, 1621-1629.	3.3	59
15	Cohort Profile: Seek and Treat for the Optimal Prevention of HIV/AIDS in British Columbia (STOP) Tj ETQq1 1 0.784314 rgBT /Overlock 1.9 56		
16	The cascade of care for opioid use disorder: a retrospective study in British Columbia, Canada. Addiction, 2020, 115, 1482-1493.	3.3	54
17	Health related quality of life trajectories of patients in opioid substitution treatment. Drug and Alcohol Dependence, 2011, 118, 259-264.	3.2	53
18	Quality of life as an outcome of opioid use disorder treatment: A systematic review. Journal of Substance Abuse Treatment, 2017, 76, 88-93.	2.8	50

#	ARTICLE	IF	CITATIONS
19	The Effects of Opioid Substitution Treatment and Highly Active Antiretroviral Therapy on the Cause-Specific Risk of Mortality Among HIV-Positive People Who Inject Drugs. <i>Clinical Infectious Diseases</i> , 2015, 61, 1157-1165.	5.8	48
20	The North American Opiate Medication Initiative (NAOMI): Profile of Participants in North America's First Trial of Heroin-Assisted Treatment. <i>Journal of Urban Health</i> , 2008, 85, 812-825.	3.6	47
21	Application and Validation of Case-Finding Algorithms for Identifying Individuals with Human Immunodeficiency Virus from Administrative Data in British Columbia, Canada. <i>PLoS ONE</i> , 2013, 8, e54416.	2.5	46
22	Ending the HIV epidemic in the USA: an economic modelling study in six cities. <i>Lancet HIV</i> , 2020, 7, e491-e503.	4.7	44
23	Cost-Effectiveness of Publicly Funded Treatment of Opioid Use Disorder in California. <i>Annals of Internal Medicine</i> , 2018, 168, 10.	3.9	43
24	The temporal relationship between drug supply indicators: an audit of international government surveillance systems. <i>BMJ Open</i> , 2013, 3, e003077.	1.9	40
25	Characterizing Durations of Heroin Abstinence in the California Civil Addict Program: Results From a 33-Year Observational Cohort Study. <i>American Journal of Epidemiology</i> , 2013, 177, 675-682.	3.4	40
26	The causal effect of opioid substitution treatment on HAART medication refill adherence. <i>Aids</i> , 2015, 29, 965-973.	2.2	40
27	The effect of motivational status on treatment outcome in the North American Opiate Medication Initiative (NAOMI) study. <i>Drug and Alcohol Dependence</i> , 2010, 111, 161-165.	3.2	39
28	Short term health-related quality of life improvement during opioid agonist treatment. <i>Drug and Alcohol Dependence</i> , 2015, 157, 121-128.	3.2	39
29	Gender differences in mortality among treated opioid dependent patients. <i>Drug and Alcohol Dependence</i> , 2015, 155, 228-235.	3.2	39
30	Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs?. <i>PLoS ONE</i> , 2015, 10, e0143836.	2.5	37
31	The costs of crime during and after publicly funded treatment for opioid use disorders: a population-level study for the state of California. <i>Addiction</i> , 2017, 112, 838-851.	3.3	37
32	Scientific and political challenges in North America's first randomized controlled trial of heroin-assisted treatment for severe heroin addiction: Rationale and design of the NAOMI study. <i>Clinical Trials</i> , 2009, 6, 261-271.	1.6	36
33	Cost-effectiveness of population-level expansion of highly active antiretroviral treatment for HIV in British Columbia, Canada: a modelling study. <i>Lancet HIV</i> , 2015, 2, e393-e400.	4.7	36
34	The impact of localized implementation: determining the cost-effectiveness of HIV prevention and care interventions across six United States cities. <i>Aids</i> , 2020, 34, 447-458.	2.2	36
35	Disparities in the Burden of HIV/AIDS in Canada. <i>PLoS ONE</i> , 2012, 7, e47260.	2.5	36
36	The quality of eight health status measures were compared for chronic opioid dependence. <i>Journal of Clinical Epidemiology</i> , 2010, 63, 1132-1144.	5.0	33

#	ARTICLE	IF	CITATIONS
37	Characterizing retention in HAART as a recurrent event process. <i>Aids</i> , 2015, 29, 1681-1689.	2.2	33
38	The effect of public health-oriented drug law reform on HIV incidence in people who inject drugs in Tijuana, Mexico: an epidemic modelling study. <i>Lancet Public Health</i> , The, 2018, 3, e429-e437.	10.0	33
39	Cohort Profile: HAART Observational Medical Evaluation and Research (HOMER) Cohort. <i>International Journal of Epidemiology</i> , 2015, 44, 58-67.	1.9	31
40	Relative effects of antiretroviral therapy and harm reduction initiatives on HIV incidence in British Columbia, Canada, 1996â€“2013: a modelling study. <i>Lancet HIV</i> , the, 2017, 4, e303-e310.	4.7	31
41	Building the Case for Localized Approaches to HIV: Structural Conditions and Health System Capacity to Address the HIV/AIDS Epidemic in Six US Cities. <i>AIDS and Behavior</i> , 2018, 22, 3071-3082.	2.7	31
42	Developing a dynamic HIV transmission model for 6 U.S. cities: An evidence synthesis. <i>PLoS ONE</i> , 2019, 14, e0217559.	2.5	31
43	The Potential Epidemiological Impact of Coronavirus Disease 2019 (COVID-19) on the Human Immunodeficiency Virus (HIV) Epidemic and the Cost-effectiveness of Linked, Opt-out HIV Testing: A Modeling Study in 6 US Cities. <i>Clinical Infectious Diseases</i> , 2021, 72, e828-e834.	5.8	30
44	A Costâ€Effectiveness Analysis of Propofol versus Midazolam for Procedural Sedation in the Emergency Department. <i>Academic Emergency Medicine</i> , 2008, 15, 32-39.	1.8	29
45	Offender Diversion Into Substance Use Disorder Treatment: The Economic Impact of Californiaâ€™s Proposition 36. <i>American Journal of Public Health</i> , 2013, 103, 1096-1102.	2.7	29
46	Utilization and outcomes of detoxification and maintenance treatment for opioid dependence in publicly-funded facilities in California, USA: 1991â€“2012. <i>Drug and Alcohol Dependence</i> , 2014, 143, 149-157.	3.2	29
47	Measuring benefits of opioid misuse treatment for economic evaluation: healthâ€related quality of life of opioidâ€dependent individuals and their spouses as assessed by a sample of the US population. <i>Addiction</i> , 2016, 111, 675-684.	3.3	29
48	HIV-1 Disease Progression During Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 63, 653-659.	2.1	28
49	Progress towards the United Nations 90â€90â€90 and 95â€95â€95 targets: the experience in British Columbia, Canada. <i>Journal of the International AIDS Society</i> , 2017, 20, e25011.	3.0	28
50	Inability to access health and social services associated with mental health among people who inject drugs in a Canadian setting. <i>Drug and Alcohol Dependence</i> , 2016, 168, 22-29.	3.2	27
51	Double-blind injectable hydromorphone versus diacetylmorphine for the treatment of opioid dependence: A pilot study. <i>Journal of Substance Abuse Treatment</i> , 2010, 38, 408-411.	2.8	26
52	A historical review of HIV prevention and care initiatives in British Columbia, Canada: 1996â€“2015. <i>Journal of the International AIDS Society</i> , 2017, 20, 21941.	3.0	26
53	Evaluation of risk mitigation measures for people with substance use disorders to address the dual public health crises of COVID-19 and overdose in British Columbia: a mixed-method study protocol. <i>BMJ Open</i> , 2021, 11, e048353.	1.9	26
54	Development and Calibration of a Dynamic HIV Transmission Model for 6 US Cities. <i>Medical Decision Making</i> , 2020, 40, 3-16.	2.4	25

#	ARTICLE	IF	CITATIONS
55	“Ending the Epidemic” Will Not Happen Without Addressing Racial/Ethnic Disparities in the United States Human Immunodeficiency Virus Epidemic. <i>Clinical Infectious Diseases</i> , 2020, 71, 2968-2971.	5.8	25
56	Effectiveness of diacetylmorphine versus methadone for the treatment of opioid dependence in women. <i>Drug and Alcohol Dependence</i> , 2010, 111, 50-57.	3.2	24
57	High levels of opioid analgesic co-prescription among methadone maintenance treatment clients in British Columbia, Canada: Results from a population-level retrospective cohort study. <i>American Journal on Addictions</i> , 2014, 23, 257-264.	1.4	24
58	Increases in the availability of prescribed opioids in a Canadian setting. <i>Drug and Alcohol Dependence</i> , 2012, 126, 7-12.	3.2	23
59	Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria. <i>Aids</i> , 2013, 27, 1159-1165.	2.2	23
60	Characterizing longitudinal health state transitions among heroin, cocaine, and methamphetamine users. <i>Drug and Alcohol Dependence</i> , 2014, 140, 69-77.	3.2	23
61	Cost-effectiveness Analysis Along the Continuum of HIV Care: How Can We Optimize the Effect of HIV Treatment as Prevention Programs?. <i>Current HIV/AIDS Reports</i> , 2014, 11, 468-478.	3.1	21
62	Dynamics in the costs of criminality among opioid dependent individuals. <i>Drug and Alcohol Dependence</i> , 2014, 144, 193-200.	3.2	21
63	Development and Validation of a Composite Programmatic Assessment Tool for HIV Therapy. <i>PLoS ONE</i> , 2012, 7, e47859.	2.5	21
64	Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2008, 35, 1729-36.	2.0	21
65	Estimating the economic value of British Columbia's domestic cannabis market: Implications for provincial cannabis policy. <i>International Journal of Drug Policy</i> , 2012, 23, 436-441.	3.3	20
66	Ending the Epidemic in America Will Not Happen if the Status Quo Continues: Modeled Projections for Human Immunodeficiency Virus Incidence in 6 US Cities. <i>Clinical Infectious Diseases</i> , 2019, 69, 2195-2198.	5.8	20
67	Costs of Health Resource Utilization Among HIV-Positive Individuals in British Columbia, Canada: Results From a Population-Level Study. <i>Pharmacoeconomics</i> , 2015, 33, 243-253.	3.3	19
68	Cost-Effectiveness of the “One4All”™ HIV Linkage Intervention in Guangxi Zhuang Autonomous Region, China. <i>PLoS ONE</i> , 2016, 11, e0167308.	2.5	19
69	Impact of the recall period on measuring health utilities for acute events. <i>Health Economics (United Kingdom)</i> , 2018, 33, 1784-1801.	1.7	18
70	Increased drug use and the timing of social assistance receipt among people who use illicit drugs. <i>Social Science and Medicine</i> , 2016, 171, 94-102.	3.8	18
71	Combined estimation of disease progression and retention on antiretroviral therapy among treated individuals with HIV in the USA: a modelling study. <i>Lancet HIV</i> , 2019, 6, e531-e539.	4.7	18
72	Cohort profile: the Comparative Outcomes And Service Utilization Trends (COAST) Study among people living with and without HIV in British Columbia, Canada. <i>BMJ Open</i> , 2018, 8, e019115.	1.9	17

#	ARTICLE	IF	CITATIONS
73	Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: a population-based observational study protocol in British Columbia, Canada. <i>BMJ Open</i> , 2020, 10, e036102.	1.9	17
74	The Cost-Effectiveness of Three Strategies for the Surgical Treatment of Symptomatic Primary Hyperparathyroidism. <i>Annals of Surgical Oncology</i> , 2008, 15, 2653-2660.	1.5	16
75	Process Monitoring of an HIV Treatment as Prevention Program in British Columbia, Canada. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, e94-e109.	2.1	16
76	The need for standardisation of the HIV continuum of care. <i>Lancet HIV</i> , 2015, 2, e225-e226.	4.7	16
77	Opioid Use Disorder and Perinatal Outcomes. <i>Pediatrics</i> , 2021, 148, .	2.1	16
78	The Cost-Effectiveness of Human Immunodeficiency Virus Testing and Treatment Engagement Initiatives in British Columbia, Canada: 2011–2013. <i>Clinical Infectious Diseases</i> , 2018, 66, 765-777.	5.8	15
79	Developing a patient-reported experience questionnaire with and for people who use drugs: A community engagement process in Vancouver’s Downtown Eastside. <i>International Journal of Drug Policy</i> , 2018, 59, 16-23.	3.3	15
80	Joint Utility Estimators in Substance Use Disorders. <i>Value in Health</i> , 2017, 20, 458-465.	0.3	14
81	Contact Tracing for COVID-19: An Opportunity to Reduce Health Disparities and End the Human Immunodeficiency Virus/AIDS Epidemic in the United States. <i>Clinical Infectious Diseases</i> , 2020, 71, 2259-2261.	5.8	14
82	The Cost-Effectiveness and Value of Information of Three Influenza Vaccination Dosing Strategies for Individuals with Human Immunodeficiency Virus. <i>PLoS ONE</i> , 2011, 6, e27059.	2.5	14
83	Rates of new infections in British Columbia continue to decline at a faster rate than in other Canadian regions. <i>HIV Medicine</i> , 2013, 14, 581-582.	2.2	13
84	Health-Related Quality of Life in HIV-Infected and At-Risk Women. <i>Medical Decision Making</i> , 2014, 34, 800-808.	2.4	13
85	Characterizing Long-Term Health Related Quality of Life Trajectories of Individuals With Opioid Use Disorder. <i>Journal of Substance Abuse Treatment</i> , 2016, 67, 30-37.	2.8	13
86	Estimates of opioid use disorder prevalence from a regression-based multi-sample stratified capture-recapture analysis. <i>Drug and Alcohol Dependence</i> , 2020, 217, 108337.	3.2	13
87	Assessing the determinants of completing OAT induction and long-term retention: A population-based study in British Columbia, Canada. <i>Journal of Substance Abuse Treatment</i> , 2022, 133, 108647.	2.8	13
88	Assessing the effectiveness of antiretroviral regimens in cohort studies involving HIV-positive injection drug users. <i>Aids</i> , 2012, 26, 1491-1500.	2.2	12
89	Estimating State Transitions for Opioid Use Disorders. <i>Medical Decision Making</i> , 2017, 37, 483-497.	2.4	12
90	The costs of crime associated with stimulant use in a Canadian setting. <i>Drug and Alcohol Dependence</i> , 2017, 180, 304-310.	3.2	12

#	ARTICLE	IF	CITATIONS
91	Identifying mental health and substance use disorders using emergency department and hospital records: a population-based retrospective cohort study of diagnostic concordance and disease attribution. <i>BMJ Open</i> , 2019, 9, e030530.	1.9	12
92	Characteristics and Response to Treatment among Aboriginal People Receiving Heroin-assisted Treatment. <i>Canadian Journal of Public Health</i> , 2010, 101, 210-212.	2.3	11
93	Cost-Effectiveness Analysis in Implementation Science: a Research Agenda and Call for Wider Application. <i>Current HIV/AIDS Reports</i> , 2021, 18, 176-185.	3.1	11
94	The effect of homelessness on hospitalisation among patients with HIV/AIDS. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2007, 19, 546-553.	1.2	10
95	The concurrent validity and responsiveness of the health utilities index (HUI 3) among patients with advanced HIV/AIDS. <i>Quality of Life Research</i> , 2009, 18, 815-824.	3.1	10
96	Characterizing Human Immunodeficiency Virus Antiretroviral Therapy Interruption and Resulting Disease Progression Using Population-Level Data in British Columbia, 1996-2015. <i>Clinical Infectious Diseases</i> , 2017, 65, 1496-1503.	5.8	10
97	Value of Information of a clinical prediction rule: Informing the efficient use of healthcare and health research resources. <i>International Journal of Technology Assessment in Health Care</i> , 2008, 24, 112-119.	0.5	9
98	Non-HIV-related health care utilization, demographic, clinical and laboratory factors associated with time to initial retention in HIV care among HIV-positive individuals linked to HIV care. <i>HIV Medicine</i> , 2016, 17, 269-279.	2.2	9
99	Determinants of selection into buprenorphine/naloxone among people initiating opioid agonist treatment in British Columbia. <i>Drug and Alcohol Dependence</i> , 2020, 207, 107798.	3.2	9
100	Improving health equity and ending the HIV epidemic in the USA: a distributional cost-effectiveness analysis in six cities. <i>Lancet HIV</i> , 2021, 8, e581-e590.	4.7	9
101	The cascade of care for opioid use disorder among youth in British Columbia, 2018. <i>Journal of Substance Abuse Treatment</i> , 2021, 130, 108404.	2.8	9
102	Changes in the Characteristics and Levels of Comorbidity Among New Patients Into Methadone Maintenance Treatment Program in British Columbia During Its Expansion Period From 1998-2006. <i>Substance Use and Misuse</i> , 2013, 48, 671-682.	1.4	8
103	Antiretroviral Drug Costs and Prescription Patterns in British Columbia, Canada. <i>Medical Care</i> , 2014, 52, 362-369.	2.4	8
104	Increased CD4:CD8 ratio normalization with implementation of current ART management guidelines. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 729-737.	3.0	8
105	The Evolving Landscape of the Economics of HIV Treatment and Prevention. <i>PLoS Medicine</i> , 2012, 9, e1001174.	8.4	8
106	Commentary Article: Opioid use Disorder Cascade of Care Framework Design: A Roadmap. <i>Substance Abuse</i> , 2022, 43, 1207-1214.	2.3	8
107	Protocol of the impact of alternative social assistance disbursement on drug-related harm (TASA) study: a randomized controlled trial to evaluate changes to payment timing and frequency among people who use illicit drugs. <i>BMC Public Health</i> , 2016, 16, 668.	2.9	7
108	Initiating HCV treatment with direct acting agents in opioid agonist treatment: When to start for people co-infected with HIV?. <i>International Journal of Drug Policy</i> , 2017, 47, 169-176.	3.3	7

#	ARTICLE	IF	CITATIONS
109	Structural Design and Data Requirements for Simulation Modelling in HIV/AIDS: A Narrative Review. <i>Pharmacoeconomics</i> , 2019, 37, 1219-1239.	3.3	7
110	Why Maximizing Quality-Adjusted Life Years, rather than Reducing HIV Incidence, Must Remain Our Objective in Addressing the HIV/AIDS Epidemic. <i>Journal of the International Association of Providers of AIDS Care</i> , 2019, 18, 232595821882196.	1.5	6
111	Non-disclosure of drug use in outpatient health care settings: Findings from a prospective cohort study in Vancouver, Canada. <i>International Journal of Drug Policy</i> , 2020, 84, 102873.	3.3	6
112	Characterizing opioid agonist treatment discontinuation trends in British Columbia, Canada, 2012–2018. <i>Drug and Alcohol Dependence</i> , 2021, 225, 108799.	3.2	6
113	The “Expanded HIV care in opioid substitution treatment” (EHOST) cluster-randomized, stepped-wedge trial: A study protocol. <i>Contemporary Clinical Trials</i> , 2015, 45, 201-209.	1.8	5
114	How simulation modeling can support the public health response to the opioid crisis in North America: Setting priorities and assessing value. <i>International Journal of Drug Policy</i> , 2021, 88, 102726.	3.3	5
115	Cohort profile: The provincial substance use disorder cohort in British Columbia, Canada. <i>International Journal of Epidemiology</i> , 2021, 49, 1776-1776.	1.9	5
116	Increasing availability of illicit drugs among people who inject drugs in Bangkok, Thailand. <i>Drug and Alcohol Dependence</i> , 2013, 132, 251-256.	3.2	4
117	The causal effect of opioid substitution treatment on highly active antiretroviral treatment adherence. <i>Drug and Alcohol Dependence</i> , 2015, 146, e53-e54.	3.2	4
118	Impact of Patient–Provider Attachment on Hospital Readmissions Among People Living With HIV: A Population-Based Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 551-558.	2.1	4
119	Heterogeneity in the costs of medical care among people living with HIV/AIDS in the United States. <i>Aids</i> , 2019, 33, 1491-1500.	2.2	4
120	Dissemination Science to Advance the Use of Simulation Modeling: Our Obligation Moving Forward. <i>Medical Decision Making</i> , 2020, 40, 718-721.	2.4	4
121	Ending the HIV Epidemic Among Persons Who Inject Drugs: A Cost-Effectiveness Analysis in Six US Cities. <i>Journal of Infectious Diseases</i> , 2020, 222, S301-S311.	4.0	4
122	High Prevalence of Unmet Healthcare Need among People who use Illicit Drugs in a Canadian Setting with Publicly-Funded Interdisciplinary Primary Care Clinics. <i>Substance Abuse</i> , 2021, 42, 760-766.	2.3	4
123	Can the “Ending the HIV Epidemic” initiative transition the USA towards HIV/AIDS epidemic control?. <i>Aids</i> , 2020, 34, 2325-2328.	2.2	4
124	Development and validation of health system performance measures for opioid use disorder in British Columbia, Canada. <i>Drug and Alcohol Dependence</i> , 2022, 233, 109375.	3.2	4
125	M2HepPrEP: study protocol for a multi-site multi-setting randomized controlled trial of integrated HIV prevention and HCV care for PWID. <i>Trials</i> , 2022, 23, 341.	1.6	4
126	Evidence-based drug policy: It starts with good evidence and ends with policy reform. <i>International Journal of Drug Policy</i> , 2012, 23, 423-425.	3.3	3

#	ARTICLE	IF	CITATIONS
127	Informing Targeted Interventions to Optimize the Cascade of HIV Care Using Cluster Analyses of Health Resource Use Among People Living with HIV/AIDS. <i>AIDS and Behavior</i> , 2018, 22, 234-244.	2.7	3
128	Prioritizing Additional Data Collection to Reduce Decision Uncertainty in the HIV/AIDS Response in 6 US Cities: A Value of Information Analysis. <i>Value in Health</i> , 2020, 23, 1534-1542.	0.3	3
129	Opioid agonist treatment uptake within provincial correctional facilities in British Columbia, Canada. <i>Addiction</i> , 2022, 117, 1353-1362.	3.3	3
130	The rise of marijuana and the fall of cocaine in the <scp>United States</scp>: for better, for worse?. <i>Addiction</i> , 2015, 110, 737-738.	3.3	2
131	Opioid analgesic prescribing for opioid-naïve individuals prior to identification of opioid use disorder in British Columbia, Canada. <i>Addiction</i> , 2021, 116, 3422-3432.	3.3	2
132	The Potential Epidemiological Impact of COVID-19 on the HIV/AIDS Epidemic and the Cost-Effectiveness of Linked, Opt-Out HIV Testing: A Modeling Study in Six US Cities. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
133	Human Immunodeficiency Virus transmission by HIV risk group and along the HIV care continuum. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, Publish Ahead of Print, .	2.1	2
134	Suboptimal nonmedical qualities of primary care linked with care avoidance among people who use drugs in a Canadian setting amid an integrated health care reform. <i>Journal of Substance Abuse Treatment</i> , 2022, 139, 108784.	2.8	2
135	High levels of opioid analgesic co-prescription among methadone maintenance treatment clients in British Columbia, Canada: Results from a population-level retrospective cohort study. <i>American Journal on Addictions</i> , 2013, 23, n/a-n/a.	1.4	1
136	Geographic variation in the costs of medical care for people living with HIV in British Columbia, Canada. <i>BMC Health Services Research</i> , 2019, 19, 626.	2.2	1
137	The Causal Effect of Opioid Agonist Treatment on Adherence to Direct-Acting Antiviral Treatment for Hepatitis C Virus. <i>Open Forum Infectious Diseases</i> , 2020, 7, .	0.9	1
138	The effect of British Columbia's Pharmacare coverage expansion for opioid agonist treatment. <i>Health Economics (United Kingdom)</i> , 2021, 30, 1222-1238.	1.7	1
139	Non-inferior antibody levels for HPV16/18 after extended two-dose schedules compared with a six-month interval: findings of a systematic review and meta-analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3554-3561.	3.3	1
140	The effect of a methadone reformulation on opioid agonist treatment outcomes: A population-based study in British Columbia, Canada, 2013-14. <i>Journal of Substance Abuse Treatment</i> , 2021, , 108714.	2.8	1
141	Response to Lancaster et al. generalizability and scalability of HIV "treatment as prevention"™. <i>Aids</i> , 2013, 27, 2319-2320.	2.2	0
142	Commentary on Krawczyk et al. (2020): Reinforcing the case for evidence-based treatment of opioid use disorder. <i>Addiction</i> , 2020, 115, 1695-1696.	3.3	0
143	Diagnosis of Opioid Use Disorder by Youths Assessed in Acute Care Settings in British Columbia, Canada. <i>Journal of Pediatrics</i> , 2021, 232, 243-250.	1.8	0
144	Attributing health benefits to preventing HIV infections versus improving health outcomes among people living with HIV. <i>Aids</i> , 2021, Publish Ahead of Print, 2169-2179.	2.2	0